Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching
To assess the longitudinal production of anti-adalimumab antibody (AAA) and baseline risk factors for this antibody development in juvenile idiopathic arthritis (JIA) patients initiating adalimumab (ADA).
Thirty consecutive JIA patients under ADA therapy were prospectively followed. JIA clinical/laboratorial/treatment data and sera for ADA and AAA assays (ELISA and bridging ELISA) were obtained at baseline (BL), 2 months (2M), 3 months (3M), 6 months (6M), 12 months (12M), and 24 months (24M). Patients with therapy failure requiring ADA withdrawn had their sera evaluated at their last medical visit prior to biologic switch (blinded to ADA and AAA levels).
AAA was absent at BL, first detected at 2M after ADA initiation in 2/30 (7%) patients with a significant increase at 3M (10/29 (34%), p = 0.013) and no major change in 6M (11/30 (37%)) and 12M (9/26 (35%)). Of note, at 3M, AAA levels correlated negatively with ADA levels (r = − 0.781, p = 0.0001). Analysis of BL predictors revealed a significantly higher risk of developing AAA in patients with female gender (OR 21; 95% CI 1.08–406.57; p = 0.044), ESR > 30 mm/1st hour (OR 5.44; 95% CI 1.04–28.53; p = 0.045), and leflunomide use (OR 9.33; 95% CI 1.51–57.66; p = 0.016). In contrast, concomitant use of methotrexate was protective for AAA appearance (OR 0.08; 95% CI 0.01–0.53; p = 0.009). After 12M of ADA, 60% of AAA-positive patients required drug switch for drug failure compared with 15% in AAA-negative group (p = 0.03).
• Anti-adalimumab antibodies (AAA) production kinetics demonstrated a timely significant increase starting at 3M in juvenile idiopathic arthritis (JIA) patients under adalimumab therapy
• Female gender, increased ESR, and leflunomide use were identified as relevant risk factors for AAA production in JIA, whereas methotrexate was protective
KeywordsJuvenile idiopathic arthritis Adalimumab Anti-adalimumab antibody Immunogenicity
This study was supported by grants from Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2015/03756-4 to NEA, CAS, SGP and EB), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 303422/2015-7 to CAS and 305068/2014-8 to EB), and by Núcleo de Apoio à Pesquisa “Saúde da Criança e do Adolescente” da USP (NAP-CriAd) to CAS.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 2.Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A (2008) Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820. https://doi.org/10.1056/NEJMoa0706290 CrossRefPubMedGoogle Scholar
- 4.Marino A, Real-Fernández F, Rovero P, Giani T, Pagnini I, Cimaz R, Simonini G (2018) Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations. Clin Rheumatol 37(5):1407–1411. https://doi.org/10.1007/s10067-018-4057-7 CrossRefPubMedGoogle Scholar
- 5.Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, Iwata N, Murata T, Okafuji I, Miyoshi M, Onoe Y, Kawano Y, Kinjo N, Mori M, Mozaffarian N, Kupper H, Santra S, Patel G, Kawai S, Yokota S (2012) Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 31(12):1713–1721. https://doi.org/10.1007/s10067-012-2082-5 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Burgos-Vargas R, Tse SM, Horneff G, Pangan AL, Kalabic J, Goss S, Unnebrink K, Anderson JK (2015) A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res 67(11):1503–1512. https://doi.org/10.1002/acr.22657 CrossRefGoogle Scholar
- 8.Petty RR, Southwood T, Manners P, Baum J, Glass DN, Goldenber J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P, International League of Associations for Rheumatology (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2:390–392Google Scholar
- 9.Machado CS, Ruperto N, Silva CH, Ferriani VP, Roscoe I, Campos LM, Oliveira SK, Kiss MH, Bica BE, Sztajnbok F, Len CA, Melo-Gomes JA, Paediatric Rheumatology International Trials Organisation (2001) The Brazilian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19(4 Suppl 23):S25–S29PubMedGoogle Scholar
- 11.Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, Paediatric Rheumatology International Trials Organisation (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658–666. https://doi.org/10.1002/art.24516 CrossRefGoogle Scholar
- 12.van Riel PL (2014) The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 32(5 Suppl 85):S-65-74.Google Scholar
- 13.Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209. https://doi.org/10.1002/1529-0131(199707)40:7%3C1202::AID-ART3%3E3.0.CO;2-R CrossRefPubMedGoogle Scholar
- 14.Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63(4):465–482. https://doi.org/10.1002/acr.20460 CrossRefGoogle Scholar
- 15.Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators (2015) Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Arthritis Rheum 67(8):2011–2019. https://doi.org/10.1002/art.39169 CrossRefGoogle Scholar
- 17.Maneiro JR, Salgado E, Gomez-Reino JJ (2013) Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 173(15):1416–1428. https://doi.org/10.1001/jamainternmed.2013.7430 CrossRefPubMedGoogle Scholar
- 18.Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, Bardales R, Elashoff D, Vangala S, Furst DE (2015) Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A Systematic Review and Meta-Analysis. BioDrugs 29(4):241–258. https://doi.org/10.1007/s40259-015-0134-5 CrossRefPubMedGoogle Scholar
- 19.Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MÁ, Monjo I, Nuño L, Nozal P, Pascual-Salcedo D, Balsa A (2019) The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol 38(3):949–954. https://doi.org/10.1007/s10067-018-4355-0 CrossRefPubMedGoogle Scholar